UroAlert - GU Oncology Weekly

October 30, 2025

Videos

Peer-to-Peer Clinical Conversations

Final Results of the SunRISe-4 Study in Muscle-Invasive Bladder Cancer - Andrea Necchi

Andrea Necchi

Andrea Necchi presents final SunRISe-4 results, evaluating neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab versus cetrelimab monotherapy in cisplatin-ineligible/refusing muscle-invasive bladder cancer patients.

Phase II LUNAR Trial Results: Adding Lutetium PSMA to SBRT for Oligorecurrent Prostate Cancer - Amar Kishan

Amar Kishan

Amar Kishan presents results from the Phase II LUNAR trial, revealing significant benefits of combining radioligand therapy with stereotactic radiation for oligorecurrent prostate cancer.

Beyond the Abstracts

Effectiveness of Nivolumab-Based Immunotherapy and Prognostic Stratification by the Meet-URO Score in Real-World Older Patients with Metastatic Renal Cell Carcinoma - Beyond the Abstract

Impact of Metastasis-Directed Therapy Guided by Different PET/CT Radiotracers on Distant and Local Disease Control in Oligorecurrent Hormone-sensitive Prostate Cancer: A Secondary Analysis of the PRECISE-MDT Study - Beyond the Abstract

Conference Coverage

ESMO 2025: Artificial Intelligence Predicts Molecular Subtypes and Outcomes in Muscle-Invasive Bladder Cancer from Whole Slide Images

ESMO 2025: Intravesical Recombinant BCG Followed by Perioperative Chemo-Immunotherapy (Chemo-IO) for Patients with Muscle-Invasive Bladder Cancer (MIBC): Interim Analysis of SAKK 06/19 Study

ESMO 2025: Multi Cycle Dosimetry of the Albumin Binding PSMA Ligand [¹⁷⁷Lu]Ludotadipep in Metastatic Castration Resistant Prostate Cancer: Phase II Trial Results

ESMO 2025: Efficacy and Safety of 177Lu-PSMA-617 (LuPSMA) in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ESMO 2025: De-Escalation of Therapy with Androgen Receptor Pathway Inhibitors or Docetaxel by Using PSMA PET/CT in Metastatic Castration-Resistant Prostate Cancer Patients: Study Results from a Dutch Cohort

Physician-Scientist Review Articles

Diagnostic Accuracy of VI-RADS for Determining Muscle Invasion - Expert Commentary

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Ferring Highlights New Real-World Research with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Clinical Practice

ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC).

Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer

Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.

T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunological sex differences in bladder cancer.

Association Between Baseline Neutrophil-to-Lymphocyte Ratio and Short-Term Urinary Quality of Life During BCG Induction in Male Patients with Non-Muscle-Invasive Bladder Cancer: A Prospective Observational Study.

Bridging Perspectives: Integrating urologist and cytopathologist insights of urine cytology.

Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer.

Guidance for avoiding patient pain and discomfort during transurethral cystoscopy.

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.

Case Report: Could genetic factors influence the outcomes of first-line enfortumab vedotin plus pembrolizumab therapy in patients with metastatic urothelial carcinoma? Two cases of patients harbouring a BRCA mutation.

Gender Disparities in Health-related Quality of Life Outcomes Following Radical Cystectomy for Bladder Cancer.

Harnessing genomic profiling for improved Urothelial cancer outcomes.

Surgical Consolidation in Advanced Urothelial Carcinoma After Enfortumab Vedotin and Immune Checkpoint Inhibitor - Expert Commentary

Renal Cancer

A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo).

Body Composition May Be a Novel Presurgical Risk Factor for Acute Kidney Injury among Clear Cell Renal Cell Cancer Patients Undergoing Radical Nephrectomy.

Population-based utilization and survival of competing treatments for small renal masses: The growing role of thermal ablation.

Solitary kidneys and off-clamp nephron-sparing surgery: A model to explore modifiable predictors of renal decline.

Inflammatory Markers in Combination With Multiple Patterns of Extrarenal Extension Accurately Indicate Recurrence Risk in Patients With pT3aN0M0 Clear Cell Renal Cell Carcinoma.

Open and minimally-invasive partial nephrectomy or thermal ablation for localized renal tumors in the United States: insurance claims data on perioperative outcomes and healthcare costs.

Application of Machine Learning for Predicting Progression-Free and Overall Survival in Patients With Renal Cell Carcinoma.

Management of Renal Cell Carcinoma of Variant Histology.

Novel pembrolizumab-based treatments as first-line therapy in advanced clear cell renal cell carcinoma: Substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial.

Comparison of health economics in robot-assisted partial nephrectomy and CT-guided cryoablation for the management of T1 renal cell carcinoma: an analysis of a prospective Danish cohort.

Updated 2025 French Guidelines for Renal Cell Carcinoma.

Prostate Cancer

Targeting Histone H2B Acetylated Enhanceosomes via p300/CBP Degradation in Prostate Cancer - Beyond the Abstract

Cost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation.

Urodynamic Changes Following a Staged Trial of Sacral Neuromodulation in Patients With Detrusor Underactivity

Individual income and race associated differences in prostate cancer mortality in a statewide registry.

Long-term follow-up after initial negative prostate biopsy-comparison of conventional transrectal ultrasound biopsy and mpMRI/transrectal ultrasound fusion guided biopsy.

Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study.

Efficacy of [18F]PSMA-1007 PET/CT in Primary Staging of Prostate Carcinoma: A Systematic Review and Metaanalysis.

Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer.

Real-world Evidence on Baseline Characteristics and Treatment in Metastatic Hormone-sensitive Prostate Cancer: Findings from the PIONEER 2.0 Big Data Investigation Group.

Treatment of aggressive prostate cancer with triptorelin in real life in France: the TALISMAN study.

French recommendations from the AFU Cancer Committee for prostate cancer 2025 Summary of changes.

4K density: Adjusting the 4Kscore for prostate volume to improve risk stratification of clinically significant prostate cancer in men undergoing prostate biopsy.

Downstream Impact of Social Media Use and Variable Quality of Online Information About Prostate Cancer.

Options in nuclear medicine for advanced prostate cancer in practice.

Age-Specific racial disparities in the incidence of fatal prostate cancer: an analytic deconstruction.

Clinical Oncological Tolerance of Testosterone Replacement Therapy Over Two Years Among Patients With High-Risk or Very High-Risk Prostate Cancer Undergoing Radiotherapy.

Should MRI-invisible low-risk prostate cancer be managed differently? A retrospective study of upgrading risk and future intervention.

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.

Genomic Alterations and Associated Outcomes in Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer treated with 177Lu-PSMA-617.

PACT is requisite for prostate cancer cell proliferation.

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study.

Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.

Comparison of oncologic outcomes following robot-assisted radical prostatectomy in high- and very high-risk prostate cancer based on the 2025 National Comprehensive Cancer Network risk stratification.

The intersection of race and adiposity in prostate cancer: a narrative review.

Prostate cancer diagnostics: evolution over 30 years and the impact of education level - a prospective population-based study.

CT online adaptive radiotherapy is associated with dosimetric and acute toxicity improvements in prostate cancer treatment.

Prostate-specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long-term survival.

Impact of multiparametric MRI and prostate biopsies on anxiety and quality of life in men with suspected prostate cancer.

Transcriptomic predictors of prostate cancer recurrence following focal cryotherapy: a pooled analysis of phase II trial and prospective cohort data.

Upper Tract Tumors

Serum lactate Dehydrogenase-to-Albumin ratio in upper tract urothelial carcinoma: A promising prognostic biomarker.

Impact of ureteroscopy on nephroureterectomy and standards of care compliance in upper tract urothelial carcinoma: the BAUS UK I-DUNC audit.

Exploring the role of thulium fiber laser in conservative treatment of UTUC: oncological and surgical outcomes.

A novel one-position versus conventional surgical approach for the treatment of upper urinary tract urothelial carcinoma: a multicenter cohort study based in western China.

Testicular Cancer

Tumor mutational burden, gene expression patterns, and immune-cell deconvolution in testicular germ cell tumors.

Testicular germ cell tumors and molecular biomarkers.

Comprehensive analysis of microRNA expression provides mechanistic insights into transcriptomic alteration in primary and metastatic testicular germ cell tumors.

Prevalence of Fertility Preservation Counseling and Sperm Cryopreservation Amongst Males with Testis Cancer.

Retroperitoneal Lymphadenectomy (RPLND) for the Treatment of Testicular Germ Cell Tumors-Open or Robotic? pro Open Surgery : RPLND in the Management of Testis Cancer - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC